Forward Pharma A/S is a Danish biopharmaceutical company preparing to initiate a clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$4.48 +0.18 (4.19%)
As of 06/24/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.